Compare Five9 Inc (FIVN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Five9 Inc trades at $24.86 (market cap $1.90B), while State Street SPDR S&P Biotech ETF trades at $153.75. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Five9 Inc nearer its low. Which is the better fit depends on your goals.
| FIVN | XBI | |
|---|---|---|
Market Cap | $1.90B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $29.16 | $164.28 |
52-Week Low | $13.61 | $85.16 |
Enterprise Value | $1.98B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $25.58, down 0.89% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $27.00. The company has shown consistent revenue growth, reaching $1.15 billion in 2025, and has beaten earnings estimates for the last three quarters. Recent news highlights include new executive appointments and AI product launches, though some legal scrutiny regarding fiduciary duties exists.
The outlook is positive given strong earnings beats and revenue growth, but risks include high valuation multiples, negative net cash flow, and ongoing legal investigations. Analyst sentiment remains largely bullish, supporting potential upside to the price target.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
